PARP inhibitor, which is a candidate for CDK12 mutation-positive cancer, had not yet been covered by Japan’s health insurance; thus, he continued CBDCA + CPT-11 therapy as the tenth-line therapy for 3 months, resulting in a gradually increasing PSA level and a generally good performance status. The gene discussed is KLK3; the disease is cancer.